Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963406 | 0.85 | CYP3A4 (0.43) | ALDH1A1RECQLGAATDP1CYP3A4 | |
| SCHEMBL685644 | 0.78 | ALDH1A1 (0.48) | ALDH1A1RECQLGAATDP1CYP3A4 | |
| SCHEMBL1726314 | 0.77 | LMNA (0.39) | ALDH1A1GAATDP1CYP3A4MEN1 | |
| SCHEMBL13761754 | 0.76 | CA2 (0.41) | ALDH1A1GAATDP1CYP3A4MEN1 | |
| SCHEMBL13379390 | 0.76 | CYP3A4 (0.35) | TDP1CYP3A4KCNA3 | |
| SCHEMBL1726701 | 0.74 | LTA4H (0.47) | ALDH1A1TDP1CYP3A4MEN1KMT2A | |
| SCHEMBL6860913 | 0.73 | CYP3A4 (0.36) | ALDH1A1TDP1CYP3A4ESR1ESR2 | |
| SCHEMBL30492595 | 0.72 | HTT (0.37) | ALDH1A1TDP1CYP3A4MEN1KMT2A | |
| SCHEMBL13379304 | 0.72 | KCNA3 (0.32) | TDP1CYP3A4KCNA3 | |
| SCHEMBL1726193 | 0.72 | LTA4H (0.47) | ALDH1A1CYP3A4MEN1KMT2AESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309167-B2 | Process for oligomerization of olefins that uses a catalytic composition that comprises an organometallic complex that contains an alkoxy ligand that is functionalized by a heteroatom | IFP Energies Nouvelles (FR) | 2016-04-12 | — | — | US | disclosed |
| US-9309167-B2 | Process for oligomerization of olefins that uses a catalytic composition that comprises an organometallic complex that contains an alkoxy ligand that is functionalized by a heteroatom | IFP Energies Nouvelles (FR) | 2016-04-12 | — | — | US | disclosed |
| US-8624042-B2 | Process for dimerization of ethylene to but-1-ene using a composition comprising a titanium-based complex and an alkoxy ligand functionalized by a heteroatom | IFP Energies Nouvelles (FR) | 2014-01-07 | — | — | US | disclosed |
| US-8624042-B2 | Process for dimerization of ethylene to but-1-ene using a composition comprising a titanium-based complex and an alkoxy ligand functionalized by a heteroatom | IFP Energies Nouvelles (FR) | 2014-01-07 | — | — | US | disclosed |
| US-20130217941-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS AN ALKOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | IFP Energies Nouvelles (FR) | 2013-08-22 | — | — | US | disclosed |
| US-20130217941-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS AN ALKOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | IFP Energies Nouvelles (FR) | 2013-08-22 | — | — | US | disclosed |
| US-20110288308-A1 | PROCESS FOR DIMERIZATION OF ETHYLENE TO BUT-1-ENE USING A COMPOSITION COMPRISING A TITANIUM-BASED COMPLEX AND AN ALKOXY LIGAND FUNCTIONALIZED BY A HETEROATOM | IFP Energies nouvelle (FR) | 2011-11-24 | — | — | US | disclosed |
| US-20110288308-A1 | PROCESS FOR DIMERIZATION OF ETHYLENE TO BUT-1-ENE USING A COMPOSITION COMPRISING A TITANIUM-BASED COMPLEX AND AN ALKOXY LIGAND FUNCTIONALIZED BY A HETEROATOM | IFP Energies nouvelle (FR) | 2011-11-24 | — | — | US | disclosed |
| US-20110287927-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS AN ALKOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | IFP Energies Nouvelles (FR) | 2011-11-24 | — | — | US | disclosed |
| US-20110287927-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS AN ALKOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | IFP Energies Nouvelles (FR) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288308-A1 | PROCESS FOR DIMERIZATION OF ETHYLENE TO BUT-1-ENE USING A COMPOSITION COMPRISING A TITANIUM-BASED COMPLEX AND AN ALKOXY LIGAND FUNCTIONALIZED BY A HETEROATOM | AS3MT, ALK, AP2M1 | ALDH1A1 1420/4885RECQL 4701/4885GAA 2154/4885 |
| US-20110287927-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS AN ALKOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | CPNE4, HAO2, AP2M1 | ALDH1A1 2242/4885RECQL 4423/4885GAA 3560/4885 |
| US-20130217941-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS AN ALKOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | CPNE4, HAO2, AP2M1 | ALDH1A1 2242/4885RECQL 4423/4885GAA 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.